Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development

- Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical development
- Internationally recognized advisers to support advancement of Actinium's differentiated radioconjugate pipeline across solid tumors and hematologic malignancies

NEW YORK, November 9, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the formation of a Scientific Advisory Board comprising five distinguished clinicians and scientists with extensive experience in oncology, nuclear medicine and radiopharmaceutical development.

The Scientific Advisory Board will provide strategic scientific and clinical guidance to support the advancement of Actinium's differentiated radioconjugate pipeline, including ATNM-400, its HER3-targeted alpha radiotherapy currently in a first-in-human Phase 1 study in metastatic castration-resistant prostate cancer. The Board's collective expertise will support clinical development strategies, trial design, patient selection, molecular imaging and therapeutic combinations across the Company's solid tumor and hematologic malignancy programs.

"We are pleased to welcome this exceptional group of clinicians and scientists to our Scientific Advisory Board at an important stage in Actinium's development," said Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals. "As we advance ATNM-400 in prostate cancer and pursue broader opportunities across solid tumors and hematologic malignancies, their collective expertise in clinical development, molecular imaging and radiopharmaceutical innovation will be invaluable in helping shape our development strategies. We believe their insights will help us prioritize the most promising opportunities, optimize clinical trial designs and accelerate the development of differentiated targeted radiotherapies for patients with significant unmet medical needs."

Actinium's Scientific Advisory Board members include:

- **Karim Fizazi, MD, PhD** - Director General, Centre Oscar Lambret, Lille, France and Professor of Oncology, Paris-Saclay University
- **Sergio A. Giralt, MD** - Deputy Division Head, Division of Hematologic Malignancies, Melvin Berlin Family Chair in Multiple Myeloma, Memorial Sloan Kettering Cancer Center
- **Jason S. Lewis, PhD** - Emily Tow Chair in Oncology; Deputy Director, Sloan Kettering Institute, Office of Science Education and Training; and Scientific Director, Radiochemistry and Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center

- **Michael J. Morris, MD** - Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center

- **Neeta Pandit-Taskar, MD, MBA** - Professor of Radiology, Chief, Division of Nuclear Medicine, University of Pittsburgh Medical Center

Scientific Advisory Board Member Profiles

Karim Fizazi, MD, PhD

Dr. Fizazi is an internationally recognized leader in prostate cancer research whose work has helped shape treatment standards for advanced disease. He founded the Prostate Cancer Consortium in Europe (PEACE), creating a collaborative network for large-scale clinical trials, and has authored more than 500 scientific publications. His clinical research spans hormonal therapies, PARP inhibitors, radioligand treatments and innovative treatment combinations. A former Head of the Department of Cancer Medicine at Gustave Roussy, he brings exceptional experience in international drug development, pivotal clinical trials and treatment sequencing for advanced and treatment-resistant prostate cancer.

Sergio A. Giralt, MD

Dr. Giralt is a pioneering transplant physician whose contributions have helped expand access to potentially curative stem cell transplantation. He and his colleagues advanced reduced-intensity conditioning regimens that enabled older and medically vulnerable patients with blood cancers to receive donor transplants, helping change clinical practice worldwide. He previously led MSK's Adult Bone Marrow Transplant Service and chaired both the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network. His distinguished expertise spans leukemia, multiple myeloma, cellular therapy and innovative conditioning strategies.

Jason S. Lewis, PhD

Dr. Lewis is an internationally recognized radiochemist and innovator at the forefront of molecular imaging and targeted radiopharmaceutical development. He was elected a Fellow of the National Academy of Inventors in 2025 in recognition of inventions supporting novel radiopharmaceuticals and antibody-based diagnostics. His laboratory develops cancer-targeting imaging and therapeutic agents, connecting radiochemistry innovation with clinical translation. With expertise spanning radiolabeled antibodies, peptides and small molecules, he brings a distinguished record of scientific innovation directly relevant to the design and development of differentiated radioconjugates.

Michael J. Morris, MD

Dr. Morris is a leading prostate cancer investigator whose work has helped advance targeted radiopharmaceuticals into clinical practice. He helped lead the pivotal Phase 3 VISION trial of lutetium-177–PSMA-617 and presented its results in the plenary session of the 2021 American Society of Clinical Oncology Annual Meeting. VISION supported the initial FDA approval of Novartis Pharma sponsored Pluvicto®, establishing a major advance for patients with metastatic castration-resistant prostate cancer. He is also the lead author of the Phase 3 PSMAfore publication. His experience combines pivotal trial development, molecular imaging and the integration of radiopharmaceuticals with other anti-cancer treatments.

Neeta Pandit-Taskar, MD, MBA

Dr. Pandit-Taskar is a distinguished nuclear medicine physician and theranostics leader whose work bridges molecular imaging, individualized radiation delivery and clinical development. She received the Society of Nuclear Medicine and Molecular Imaging's 2023 Henry N. Wagner Jr., MD, Best Paper Award for research on individualized Iomab-B dosing in the Actinium Pharmaceutical sponsored pivotal Phase 3 SIERRA trial, recognizing the meeting's top abstract. She also served as President of SNMMI's Therapy Advisory Committee Center of Excellence from 2021 to 2023. In addition to her departmental leadership, she serves as a vice-chair of clinical translation research and is a medical director of University of Pittsburgh's PET Research Center and oncologic imaging at UPMC Hillman Cancer Center, bringing expertise in imaging, dosimetry and radiopharmaceutical translation.

MSK Disclosure: Memorial Sloan Kettering (MSK) has institutional financial interests related to Actinium Pharmaceuticals.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, and is being evaluated in a first-in-human Phase 1 study in mCRPC. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the conduct, timing and results of the Company's ongoing first-in-human Phase 1 study, including the risk that interim findings are not predictive of final results and that preclinical results are not predictive of results in humans, preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors Contact:

Peter (PJ) Kelleher
LifeSci Advisors
pkelleher@lifesciadvisors.com
(617) 430-7579